Key result
Beraprost sodium significantly reduced the risk of all vascular events by approximately 39% compared to placebo in patients with peripheral arterial disease (RR 0.608, 95% CI 0.41-0.90, p=0.012).
Why the study?
Does beraprost sodium reduce vascular events in patients with intermittent claudication associated with peripheral arterial disease?
Meta-Analysis (n=1,184)
Double-blind
Randomized
Yes
Does beraprost sodium reduce vascular events in patients with intermittent claudication associated with peripheral arterial disease?
Beraprost sodium may reduce the risk of vascular events in patients with intermittent claudication associated with peripheral arterial disease over a 6-month period.
Answers are grounded in this paper and cite their sources.
Beraprost sodium may reduce vascular events in PAD; confirms benefit in meta-analysis of two placebo-controlled RCTs.
Objective : To evaluate the effect of beraprost sodium (beraprost) on the vascular events occurring in patients with peripheral arterial disease (PAD) in a meta-analysis of placebo-controlled, randomized trials.Design : Meta-analysisMethods : Among the clinical trials of beraprost in patients with intermittent claudication associated with PAD, placebo-controlled, randomized trials with vascular events as outcome measures were selected. Two trials met the criteria, each of which was a comparative trial of beraprost (40 μg t.i.d.) and placebo (t.i.d.), with a six-month follow-up period.Results : With both trials combined, the analysis included 594 patients in the beraprost group and 590 in the placebo group. The risk ratio was 0.608 (95%CI : 0.41 to 0.90, p =0.012), demonstrating the efficacy of beraprost on all vascular events. The risk ratio for lower limb deterioration was 0.598 (95% CI : 0.34 to 1.06, p =0.079), which was similar to that for all vascular events. A statistically insignificant but similar result was also obtained for cardio/cerebrovascular events with a risk ratio of 0.619 (95%CI : 0.36 to 1.07, p = 0.085). Heterogeneity between the two studies was not found for any of the events.Conclusion : The results demonstrated the efficacy of beraprost on the vascular events in patients with PAD. The potential benefit of beraprost on vascular events will require evaluation in a larger prospective investigation.
No takes yet. Share an insight, caveat, or question.
Origasa et al. (2004) conducted a meta-analysis in Peripheral arterial disease with intermittent claudication (n=1,184). Beraprost sodium vs. Placebo was evaluated on All vascular events (RR 0.608, 95% CI 0.41 to 0.90, p=0.012). Beraprost sodium significantly reduced the risk of all vascular events by approximately 39% compared to placebo in patients with peripheral arterial disease (RR 0.608, 95% CI 0.41-0.90, p=0.012).
Synapse has enriched 10 related papers. Consider them for comparative context: